Theravance Biopharma SVP Brett Grimaud Receives 37,500-Share Award

What Happened

• Brett A. Grimaud, SVP, General Counsel and Secretary of Theravance Biopharma (TBPH), was granted 37,500 shares on April 1, 2026. The Form 4 reports the acquisition as an award (transaction code A) at a reported acquisition price of $0.00 (no cash paid).
• The filing shows an award/grant rather than a market purchase or sale. Awards are typically compensation (e.g., restricted stock or RSUs) and do not by themselves indicate an immediate buy or sell in the open market.

Key Details

• Transaction date: 2026-04-01; Form 4 filed: 2026-04-03 (filed within standard two-business-day window).
• Shares granted: 37,500; reported acquisition price: $0.00.
• Shares owned after the transaction: not specified in the provided filing.
• Transaction code: A (award/grant). No footnotes or a 10b5-1 plan, tax-withholding, or cashless-sale details were reported in the supplied record.

Context

• Equity awards recorded at $0 generally reflect compensation grants (often RSUs or restricted stock) that may vest over time and can be subject to forfeiture until vested; the Form 4 does not specify vesting terms or whether shares are immediately transferable.
• Because this is a compensation award rather than a purchase or sale, it should be viewed as part of executive pay practices rather than a direct market sentiment signal.